INFECTIOUS
Infectious causes of subacute and chronic meningitis that are discussed in this article include Cryptococcus species, Coccidioides immitis, Histoplasma capsulatum, Blastomyces dermatitidis, Aspergillus fumigatus, Mycobacterium tuberculosis, and syphilis.
Tables 3-1 and 3-2 summarize the presentation, radiographic findings, and CSF findings for the most common causes of infectious meningitis. Table 3 -3 lists the recommended treatments for the most common infectious etiologies of chronic meningitis.
Cryptococcus
Cryptococcal meningitis is caused by the encapsulated yeast organism Cryptococcus neoformans. With a worldwide distribution, C. neoformans is primarily found in contaminated soil, avian excrement, and the bark of several tree species. Infection usually occurs by inhalation of the organism, followed by a respiratory infection and dissemination of the infection. 1 This organism emerged as an important opportunistic pathogen in the 1980s with the advent of HIV infection. Cryptococcal meningitis is most common in people with impaired cell-mediated immunity, especially HIV 
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infection; people with hematologic malignancies; solid-organ transplant recipients; and patients on chronic corticosteroids or other immunosuppressive therapy; but it also occurs in immunocompetent individuals. 2 Historically, the genus Cryptococcus was divided into four serotypes (A, B, C, D) using capsular assays, but recently these have been reclassified. Serotype A is now classified as C. neoformans grubii; this organism has a worldwide distribution and is the most common cause of cryptococcal meningitis in immunocompromised patients. Serotypes B and C are classified as C. neoformans gattii, and this organism causes meningitis in individuals with impaired cellmediated immunity and those who are immunocompetent. 3 C. neoformans gattii was previously thought to be rare and limited to subtropical climates until a large outbreak occurred in British Columbia in 1999. Most of these infections occurred in patients with normal immune systems. 4 Serotype D is classified as C. neoformans neoformans, is predominantly found in Western Europe, and typically affects immunocompromised patients.
In immunocompromised patients, cryptococcal meningitis is the most common systemic fungal infection and a frequent etiology of CNS infection, with a prevalence varying from 10% in the United States to as high as 30% in sub-Saharan Africa. 5 Although the incidence of cryptococcal meningitis has decreased since the introduction of combination antiretroviral therapy, it continues to be a common cause of death in many resource-limited countries. In several areas of Africa, cryptococcal meningitis is the most common cause
KEY POINTS
h Cryptococcal meningitis is most common in people with impaired cell-mediated immunity, especially HIV infection, hematologic malignancies, solid-organ transplantation, and in patients on chronic corticosteroids or other immunosuppressive therapy, but also occurs in immunocompetent individuals.
h In immunocompromised patients, cryptococcal meningitis is the most common systemic fungal infection and a frequent cause of fungal CNS infections. of meningitis, with mortality rates as high as 100% in a study of 230 adults in Zambia. 6 Clinical presentation. The clinical manifestations of infection with C. neoformans depend largely on the host immune status. Severity of infection varies from asymptomatic incidental pulmonary nodules to widely disseminated disease. Patients with HIV and CD4+ cell counts of less than 50 cells/2L are especially vulnerable to disseminated infection and meningitis. 7 Immunosuppressed patients with cryptococcal meningitis frequently present with indolent nonspecific symptoms and in some cases with isolated neurologic manifestations.
Patients with normal cellular immunity generally manifest more typical signs and symptoms of meningitis. In general, over 75% of patients present with headache and fever, which typically develop insidiously over 2 to 4 weeks. 8 Nausea, vomiting, and altered mental status occur in about half of patients. Signs and symptoms of meningismus affect less than 25% of patients. Visual symptoms, such as diplopia and blindness, occur in about 20% of patients, most often in immunocompetent patients. 9 Seizures and focal neurologic deficits occur in 10% of patients and are generally caused by space-occupying lesions such as cryptococcomas or Case 3-1 demonstrates a common presentation and clinical course in a patient with cryptococcal meningitis.
Diagnosis. The diagnosis of cryptococcal meningitis should be considered in patients presenting with a subacute presentation of headache and fever, Despite declining CSF CRAg titers, the patient continued to have persistently elevated intracranial pressure of 40 cm H 2 O. Several weeks of serial lumbar punctures and the addition of acetazolamide failed to reduce the intracranial pressure. The patient's headache, diplopia, and papilledema persisted. A repeat MRI of the brain revealed considerable progression of leptomeningeal enhancement in the posterior fossa, acute hydrocephalus, and development of early tonsillar herniation. She was referred to neurosurgery for placement of a ventriculoperitoneal shunt.
With aggressive management of elevated intracranial pressure via shunt placement and continued antifungal treatment, the patient had resolution of her neurologic symptoms. Follow-up HIV antibody test results were negative, and CD4 counts were normal. The patient was diagnosed with immunocompetent acquisition of cryptococcal meningitis, presumably from exposure to C. neoformans in the loon feces.
Comment. Cryptococcal meningitis is a common cause of chronic meningitis in patients presenting with signs and symptoms of elevated intracranial pressure. Patients are typically immunosuppressed or have an environmental exposure, such as occurred in this patient who was caring for an injured loon. This case demonstrates that fungal meningitis can initially present with a neutrophilic pleocytosis, followed by mononuclear cellular predominance on later cerebrospinal fluid analyses. rapid, and 75% sensitive, the decreasing use of microscopic evaluation of CSF in high-income countries has led to a reliance on antigen-based assays. 8 The CSF cryptococcal capsular polysaccharide antigen (CRAg) assay is both sensitive and specific for cryptococcal meningitis and also provides a quantitative titer that is useful for prognostication but has limited value for measuring response to therapy. 11 Fungal culture for the organism is 90% sensitive and can be useful for both diagnosing infection and speciation.
Laboratory results, physical examination, and neuroimaging findings may aid in determining prognosis of cryptococcal meningitis. Poor prognostic factors include low CSF glucose concentration, high CSF cryptococcal antigen titer (greater than 1:1024), high CSF lactate level, altered level of consciousness, hydrocephalus, and elevated intracranial pressure. 12 Treatment. A combination of antifungal medication and aggressive treatment of intracranial hypertension is integral to successful treatment of patients with cryptococcal meningitis. Treatment protocols involve a three-step approach: induction, consolidation, and maintenance therapy. Induction includes 2 weeks of AmB (0.7 mg/kg/d to 1 mg / kg/ d) plus flucytosine (100 mg/kg/d). Consolidation therapy is 8 weeks of fluconazole (400 mg/d), followed by maintenance therapy with fluconazole (200 mg/d) for life (see later discussion). This regimen was validated in a large double-blind randomized trial that demonstrated significant benefit of combined induction therapy over AmB alone. 11 A study comparing AmB 0.7 mg/kg daily for 21 days with liposomal AmB 4 mg/kg daily for 21 days detected no difference in clinical response, although major adverse events were less common in patients receiving liposomal AmB. This study suggests that liposomal AmB is better tolerated and equally effective treatment for cryptococcal meningitis. 13 Treatment efficacy is best monitored by clinical response to therapy, as CSF CRAg titer varies significantly; however, an increasing titer has been associated with ineffective treatment. Lifelong maintenance therapy with fluconazole is no longer required after successful immune restoration in patients who are HIV-positive. Several prospective trials suggest it is safe to discontinue maintenance therapy if the patient has an undetectable HIV viral load and CD4+ cell count greater than 100 cells/2L. 14 Elevated intracranial pressure can be managed through a variety of treatments. To date, no trials support acetazolamide as an effective treatment of elevated intracranial pressure in cryptococcal meningitis. 15 Patients with elevated intracranial pressure should undergo daily lumbar punctures to reduce opening pressure until normal opening pressure is maintained consistently. For patients requiring frequent lumbar punctures, placement of a lumbar drain or a ventriculostomy can serve as a temporary measure to control intracranial pressure. 16 A small case series supports the use of ventriculoperitoneal shunting for patients with intracranial hypertension and HIV-associated cryptococcal meningitis who do not respond to serial lumbar punctures or who require prolonged lumbar drainage. 17 A review of 27 patients with cryptococcal meningitis with elevated intracranial pressure reported good outcomes in 63% of patients who underwent ventriculoperitoneal shunting; 37% of patients had bad outcomes, defined as death or persistent vegetative state. Of note, 85% of patients with a good outcome did not have altered level of consciousness at the time of shunt placement. Poor outcomes were associated with a Glasgow Coma Scale score of less than 8 or duration of altered level of consciousness longer than 48 hours. 18 Meningitis is a devastating complication, occurring in approximately one-third to one-half of patients with disseminated disease. Rarely, central nervous system involvement will present as the first sign of infection with C. immitis. Patients with disseminated C. immitis typically will also suffer from pulmonary disease.
Clinical presentation. Meningitis due to C. immitis classically involves the basilar meninges. The most common symptom is headache, which is present in over 75% of patients. Other presenting signs and symptoms include nausea and vomiting (40%); altered mental status (39% to 73%); focal neurologic deficits, including ataxia, gait disturbance, diplopia, or facial palsies (33% to 80%); and nuchal rigidity (20%). 19 Coccidioi- Hydrocephalus, cerebral infarction, and vasculitis are potential complications of C. immitis meningitis. Communicating hydrocephalus is a well-known complication of basilar meningitis, secondary to obstruction of CSF reabsorption, and may develop during the initial or later stages of the infection. Hydrocephalus develops in about 20% to 50% of patients with C. immitis meningitis and is associated with a 12-fold increased risk of mortality. 21 Cerebral infarction and venous and dural thrombosis have been reported during initial and later stages of infection. Small and medium blood vessels are typically affected. Perivascular inflammation is typically associated with infarctions of the basal ganglia, thalamus, and cerebral white matter. 22 Diagnosis. Coccidioidomycosis can be diagnosed using serologic testing, histopathology, or culture. Identification of C. immitis spherules in tissue, sputum, bronchoalveolar lavage (BAL) fluid, or other body fluid, or a positive culture from any location in the body, is diagnostic of coccidioidal infection. Although definitive diagnosis of C. immitis meningitis requires identification or culture of the organism from the CSF, presumptive diagnosis is often sufficient to initiate treatment. CSF is typically abnormal, with a lymphocytic pleocytosis (20 h Meningitis due to C.
immitis classically involves the basilar meninges. The most common symptom is headache, which is present in over 75% of patients.
to 500 WBCs/6L), early neutrophil predominance, and low glucose concentration. Interestingly, this pathogen may cause a CSF eosinophilia in up to 70% of patients with meningitis, a finding that is relatively uncommon with other fungal pathogens. 23 Isolation of the organism from CSF culture occurs in only about 15% of cases. Identification of spherules via CSF using cytopathologic Papanicolaou stain can confirm the infection. 24 Rarely, CSF examination may reveal hyphal forms of C. immitis. Detection of antibodies to C. immitis in the CSF using the complement-fixation antibody assay is the most sensitive test for confirming meningeal infection. Repeated CSF sampling is sometimes needed to confirm the diagnosis, as antibody test results can be negative early during the course of infection (71% to 94% sensitive). Enzyme immunoassay for IgM and IgG and latex agglutination tests are less sensitive in CSF samples. 22 Although PCR assays have been used to detect C. immitis infection, they are not routinely available.
Neuroimaging with MRI is superior to CT for detecting abnormalities, which are present in up to 75% of patients with C. immitis meningitis. The most common radiographic abnormalities include hydrocephalus, basilar meningitis, and cerebral infarction. C. immitis meningitis can produce diffuse meningeal enhancement, focal or nodular enhancement, parenchymal or parameningeal abscesses, and spinal arachnoiditis. 25 Patients with abnormal MRI scans have a mortality rate of 20% to 30%, compared with 8% in patients with normal imaging studies. 21 Patients with hydrocephalus, with or without cerebral infarction, have the highest mortality rates. Patients with normal neuroimaging have significantly better prognoses.
Treatment. Oral fluconazole is the gold standard of treatment for patients with C. immitis meningitis. Practice guidelines recommend high-dose induction therapy with oral fluconazole 400 mg/d to 800 mg/d, followed by 200 mg/d to 400 mg/d indefinitely. 26 Approximately 66% to 80% of patients treated with oral azoles alone achieved initial clinical improvement or remission of meningitis. However, up to 75% of patients may relapse; therefore, lifelong prophylaxis with fluconazole 400 mg/d is recommended. 26 Without treatment, the outcome of patients with C. immitis meningitis is poor. In one study, 90% of patients died within 1 year, and 100% died within 2 years.
Treatment of C. immitis meningitis with IV AmB alone is not effective. Intrathecal amphotericin, via lumbar administration, intracisternal injection, or Ommaya reservoir administration, in combination with IV AmB, was the treatment for C. immitis meningitis prior to the advent of azole therapy, particularly fluconazole, but is no longer the initial treatment of choice. 27 For pregnant patients and those intolerant of azole treatment, intrathecal AmB is an option. Patients for whom azole therapy fails, who have complicated infections, or who worsen during initial therapy may benefit from combined use of intrathecal amphotericin with oral azole therapy. produce a large spectrum of disease, ranging from subclinical infection to disseminated disease.
Blastomycosis. B. dermatitidis, a thick-walled yeast with broad-based budding daughter cells, is endemic to the Great Lakes and Mississippi and Ohio river valleys. Like histoplasmosis, infection with blastomycosis is acquired via inhalation of spores into the lung and can manifest as pulmonary or extrapulmonary disease. Chest radiographs commonly demonstrate nodular or lobar infiltrates and cavitations. If the organism evades nonspecific host defense mechanisms in the lungs, it will convert into the yeast phase and multiply. The organism then spreads hematogenously to other organs. Inflammatory pyogranulomatous reactions occur at the initial pulmonary site and at foci of infection. Cutaneous involvement is seen in 60% of patients with blastomycosis, manifesting as verrucous or fungating lesions with irregular borders. Other sites less frequently involved include bones, joints, genitourinary system, and the CNS. 28 Clinical presentation. CNS infection with blastomycosis occurs in less than 10% of people with disseminated disease and manifests as solitary or multiple abscesses and acute or chronic meningitis. Unlike other fungal CNS infections, blastomycosis is more likely to present with focal neurologic deficits, seizures, and altered mental status, whereas symptoms of fever, headache, and meningismus are less common. Although intracranial infection results most frequently from hematogenous seeding of the brain parenchyma from the lungs, epidural extensions from overlying vertebral or skull osteomyelitis have been described. 29 Diagnosis. Diagnosis of CNS blastomycosis is often delayed because of a lack of clinical suspicion and limited tools for establishing a rapid diagnosis. Direct visualization of the organism via microscopy has been the only method of rapid diagnosis but has variable sensitivity. Lumbar puncture typically reveals elevated opening pressure, and CSF examination is notable for elevated protein concentration, low glucose concentration, and pleocytosis with neutrophilic predominance early in the disease course followed by a lymphocytic predominance. The gold standard for diagnosis remains CSF culture, which is positive in 64% of cases of blastomycosis. 30 Growth of B. dermatitidis can occur within 5 to 10 days, 31 but may take 2 to 4 weeks for definitive identification of the organism. More invasive procedures, such as brain biopsy and ventricular sampling of CSF, are more likely to provide sufficient material for definitive diagnosis and are often needed for intracranial disease. 31 Diagnostic modalities such as skin testing and serologic assays for detection of antibodies have limited sensitivity and specificity for diagnosing blastomycosis. 32 Commercially available enzyme immunoassay for detection of B. dermatitidis antigen in urine has a sensitivity of 93% and specificity of 79% but is cross-reactive with other dimorphic fungi, particularly H. capsulatum.
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Treatment. All patients with CNS blastomycosis should be treated with AmB (0.7 mg/kg/d to 1.0 mg/kg/d) to a cumulative dose of at least 2 g. Once control of the infection has been achieved, an oral azole, such as fluconazole, should be administered as consolidation therapy. Other azoles, such as voriconazole, also have adequate CNS penetration and may become primary therapies for CNS disease. Relapse after treatment with AmB occurs in less than 5% of immunocompetent patients. Patients with immunodeficiency due to HIV or immunosuppressive therapy have high rates of relapse and should be maintained on long-term secondary prophylaxis with fluconazole. Histoplasmosis. H. capsulatum obtains nutrients from bird excrement and bat guano. Infection usually requires a significant inoculum of organisms or repeated exposure. People with histoplasmosis often report travel to or reside in the Mississippi or Ohio river valleys and have a history of cleaning chicken coops or spelunking in caves with large bat populations. Histoplasmosis may produce an acute pulmonary infection with fever, chills, and pulmonary opacities. Patients with impaired cellular immunity, such as individuals who are HIV infected, typically present with chronic pulmonary symptoms with progression to severe disseminated disease. Infection disseminates hematogenously to distant sites, such as the liver, spleen, and CNS. Bone marrow involvement is common and often manifests as thrombocytopenia, anemia, or leukopenia. 35 Clinical presentation. Most patients with pulmonary histoplasmosis are asymptomatic and have resolution of the infection without therapy. It is common for individuals in the Mississippi and Ohio river valleys to have asymptomatic pulmonary nodules. The organism can become dormant in macrophages and later reactivate and cause disease. Dissemination occurs during both primary infection and reactivation of latent infection. CNS involvement occurs in less than 20% of patients with disseminated infection and most frequently affects patients with severely impaired cellular immunity, such as people who are HIV infected and those who have undergone solid-organ transplantation. Presenting symptoms typically include headache and altered mental status; although less common, patients may also present with focal neurologic deficits, seizures, encephalitis, ischemic stroke, and mass lesions.
Diagnosis. Similarly to that of blastomycosis, definitive laboratory diagnosis of histoplasmosis is difficult; clinical history of exposure remains crucial. CSF frequently demonstrates a mononuclear pleocytosis, increased protein concentration, and decreased glucose concentration. CSF culture is not sensitive for diagnosing histoplasmosis. The use of CSF and serum antigen titers and antibodies are useful, although as with blastomycosis, significant cross-reactivity occurs with other dimorphic fungi. Because meningitis is typically a result of disseminated infection, testing for the organism in the blood or bone marrow should also be considered.
Treatment. Treatment of CNS histoplasmosis is challenging. Despite treatment with AmB, 20% to 40% of patients with meningitis die of the infection and up to half of responders relapse after therapy is discontinued. The optimal treatment for H. capsulatum meningitis is AmB (0.7 mg/kg/d to 1.0 mg/kg d) to complete a total dose of 35 mg/kg during a 3-to 4-month period. To reduce the risk of relapse, fluconazole (800 mg/d) should be continued for 9 to 12 months after completion of AmB. Chronic fluconazole maintenance therapy (800 mg/d) should be considered for patients who relapse after completing a full course of therapy. Itraconazole, although more active against H. capsulatum than fluconazole, does not cross the blood-brain barrier in adequate amounts to treat CNS infection. Intrathecal administration of amphotericin directly into the ventricles, cisterna magna, or lumbar arachnoid space should be reserved for severe infections that do not respond to conventional therapy. 36 Aspergillus Aspergillus species are ubiquitous soil inhabitants that grow and survive on organic debris. This organism sporulates abundantly, releasing conidia into the atmosphere in large quantities. The conidia are small in diameter, making it possible to reach smaller areas of the lung, including the alveoli. Environmental studies indicate that humans inhale several hundred conidia per day, 37 but inhalation of organisms rarely results in disease because the conidia are eliminated efficiently by host immune mechanisms. Alveolar macrophages constitute the first line of host defense against aerosolized conidia. Neutrophils are the dominant host defense against the invasive hyphal stage. 38 Historically, disease was limited to individuals with repetitive exposure to pathogens, producing a mild condition known as farmer's lung. Aspergillus was also known to produce lung aspergillomas, characterized as an overgrowth of fungus in preexisting cavitary lung lesions. More recently, the incidence and severity of Aspergillus infection have increased because of a growing number of people living with immunosuppression, leading to disease known as invasive aspergillosis. 39 Populations significantly at risk for invasive aspergillosis include patients undergoing treatment for hematologic malignancies, recipients of allogeneic hematopoietic stem cell transplant and solid-organ transplant, people who are HIV infected, and individuals with chronic granulomatous disease. 38 Deficits in host defense mechanisms that increase susceptibility to invasive aspergillosis are complex but can be broadly divided into three groups: (1) neutropenia, (2) qualitative deficits in phagocyte function, and (3) deficits in cell-mediated immunity. 40 Clinical presentation. A. fumigatus is responsible for approximately 90% of human infections. Other members of this genus that less commonly produce human infection include A. flavus, A. terreus, A. niger, and A. nidulans. Four types of invasive aspergillosis have been described: (1) acute or chronic pulmonary aspergillosis, (2) tracheobronchitis and obstructive bronchial disease, (3) acute invasive rhinosinusitis, and (4) disseminated infection involving the brain or other organs (ie, skin, kidneys, heart, and eyes). CNS infection results from hematogenous dissemination of the organism or by direct extension from rhinosinusitis. Cerebral aspergillosis occurs in approximately 10% to 20% of patients with invasive disease. 39 CNS infection can present as a solitary mass lesion, cavernous sinus thrombosis, multiple intracranial abscesses, acute or chronic basilar meningitis, vasculitis, or myelitis. Pathologically, CNS aspergillosis has a propensity for vascular invasion, infarction, hemorrhage, and aneurysm formation; as a result, the clinical presentation may be that of cerebral vasculitis, ischemic or hemorrhagic infarction, or subarachnoid hemorrhage. Granuloma formation with necrosis is also commonly observed. An isolated abscess may be suspicious for neoplasm and, upon biopsy or extirpation, reveal a yellowish fluid or fungal hyphae upon staining.
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Case 3-2 demonstrates a classic clinical presentation of disseminated CNS aspergillosis in a heart transplant patient.
Diagnosis. Diagnosis of aspergillosis in immunocompromised patients remains difficult. As with many invasive fungal CNS infections, diagnosis is often achieved through examination of the primary entry site of infection. Thus, in patients with suspected CNS aspergillosis, it is important to examine the lungs and sinuses for evidence of infection and potential sites for obtaining biopsy or culture material. BAL cultures are nearly 50% sensitive for detecting aspergillosis in focal pulmonary lesions. Isolation of an Aspergillus species from sputum or BAL is highly predictive of invasive disease in neutropenic patients. Chest imaging can be used to support diagnosis. During early invasive pulmonary aspergillosis, the most common finding on chest CT is one or more nodules. The ''halo sign,'' a haziness surrounding a nodule or infiltrate on chest CT, is a characteristic feature of angioinvasive
KEY POINTS
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Case 3-2
A 63-year-old woman with a history of idiopathic hypertrophic cardiomyopathy and heart transplantation 6 years previously, receiving tacrolimus for immunosuppression, presented with subacute altered mental status. Initially the patient had problems with simple tasks such as operating a remote control; this progressed to an inability to perform activities of daily living. Several days prior to admission she began having visual hallucinations and worsening orientation, followed by acute onset of left hemiparesis and loss of consciousness. Further history revealed the patient had been reporting a progressive productive cough for 6 months, drenching night sweats, and a 6.8-kg (15-lb) unintentional weight loss. Examination revealed a comatose woman intubated without sedation. Her brainstem reflexes and cranial nerve examination were normal, with the exception of a left lower facial droop. She had brisk withdrawal to pain in all extremities, with a left hemiparesis and diffuse hyperreflexia. Head CT revealed hypodensity involving the left frontal and temporal lobe, right basal ganglia, and left cerebellum. Lumbar puncture yielded purulent yellow fluid with normal opening pressure, 1546 WBCs/2L (92% neutrophils, 2% lymphocytes, 6% monocytes), 14 RBCs/2L, glucose concentration of 22 mg/dL, and protein concentration of 97 mg/dL.
Antibiotics were started for treatment of suspected community-acquired bacterial meningitis. MRI of the brain revealed restricted diffusion involving the frontal, parietal, and occipital cortex, rostrum and splenium of the corpus callosum, right thalamus, and cerebellar hemispheres (Figure 3-2 Despite aggressive therapy with antiviral and antibiotic medications, the patient continued to decline clinically. CT of the chest revealed dense bilateral lower lobe consolidation and diffuse lymphadenopathy. Abdominal CT revealed a moderate amount of free fluid. BAL and paracentesis were performed. The patient rapidly progressed to septic shock and multiorgan failure and died 7 days after presentation.
BAL and paracentesis culture grew A. fumigatus 7 days after collection. The postmortem diagnosis was invasive aspergillosis with CNS involvement. Initial CSF analysis demonstrating neutrophilic pleocytosis, elevated protein, and low glucose concentration was consistent with early fungal meningitis. MRI supported angioinvasive disease by demonstrating multiple ischemic infarctions.
Comment. Aspergillus meningitis is an aggressive disease that can affect posttransplant recipients taking immunosuppressive agents. This case demonstrates the current challenges in rapidly identifying the organism and the importance of early treatment. organisms and is highly suggestive of invasive aspergillosis. Neuroimaging can be helpful in the evaluation of CNS aspergillosis. MRI of the brain can demonstrate a variety of lesions, including cerebral infarction, on diffusion-weighted imaging, hemorrhagic lesions, solid-enhancing aspergillomas, or ring-enhancing abscesses. Dural enhancement is usually seen in lesions adjacent to infected paranasal sinuses and indicates direct extension of disease. 42 In patients with Aspergillus sinusitis, endoscopy may reveal sentinel eschars along the nasal turbinates. Direct smear of brushings or biopsies of these lesions may reveal hyphae, and culture is often positive. Involvement of the ethmoid sinuses carries a particularly high risk of extension to the cavernous sinus. Ophthalmoplegia is often an early sign of cavernous sinus thrombosis that precedes radiologic confirmation. Biopsy of nasal tissue or brain biopsy of solitary lesions can provide histopathologic evidence of Aspergillus species infection and remains critical to establishing a diagnosis of sinus and intracranial disease.
Several valuable serum laboratory markers can aid in the diagnosis of invasive Aspergillus. ELISA testing for galactomannan and "-glucan, fungal cell wall constituents, should be considered. In 170 patients hospitalized in North American cancer centers at high risk for invasive mold infection, the serum galactomannan assay identified 25 of 31 patients with invasive aspergillosis (81% sensitivity) and had a specificity of 89%. In another study, the sensitivity was only 64.5% in cases of definite invasive aspergillosis. 43 CSF galactomannan assay using latex agglutination or ELISA is a useful adjunct to serum testing. The sensitivity of serial CSF testing is 70% to 90% and specificity is 86% to 71%. 44 In patients with acute myeloid leukemia and myelodysplastic syndrome, the "-glucan assay is highly sensitive for detecting early invasive fungal infections, including candidiasis, fusariosis, trichosporonosis, and aspergillosis. 45 Several PCR assays can detect Aspergillus in blood and BAL fluid samples, but experience with PCR to detect Aspergillus species in CSF samples is limited. A recent study using nested PCR assay detected Aspergillus DNA in samples from six of six patients with CNS aspergillosis. In all patients, samples obtained at the initial manifestation of CNS aspergillosis were positive by PCR. In patients with serial CSF sampling, follow-up samples obtained during antifungal treatment and after clinical improvement tested negative, suggesting this assay may be useful for determining response to therapy. 46 Treatment. Unfortunately, CNS aspergillosis, especially in an immunocompromised patient, is difficult to treat and has a high mortality rate. The newer antifungal agent voriconazole has reduced mortality in an infection previously associated with almost universal mortality. Clinical trials have demonstrated that voriconazole is more effective than AmB as initial therapy for invasive aspergillosis and is associated with significantly improved survival (71% versus 58%, respectively). 47 More recently, clinicians have combined voriconazole with caspofungin (an echinocandin) as salvage therapy in patients with invasive aspergillosis, resulting in a favorable response in 37 of 83 patients (45%). Significant interest has developed in combining an echinocandin with either an AmB preparation or a moldactive azole. Marra and colleagues reported improved survival rates in patients treated with voriconazole plus caspofungin compared to those treated with voriconazole alone. 48 Surgical debulking of CNS aspergillomas has produced long-term survival; in combination with systemic antifungal chemotherapy, extirpation or aspiration of cerebral aspergillomas can be curative. In patients with a solitary abscess, lobectomy has been performed when noneloquent areas of the brain are involved. 49 
Mycobacterium Tuberculosis
Tuberculous meningitis is caused by M. tuberculosis, an aerobic gram-positive acid-fast pleomorphic bacilli. M. tuberculosis is an intracellular pathogen that survives within the phagosome of host macrophages. Apoptosis of infected macrophages is an effective host mechanism against tuberculous bacilli. Virulent strains of M. tuberculosis have evolved several genetic mechanisms to evade host immune mechanisms. 50 Transmission occurs primarily by inhalation of airborne droplet nuclei into the lungs. M. tuberculosis multiplies in alveolar macrophages, and within weeks the bacilli can hematogenously disseminate to extrapulmonary sites. In distant organs, including the meninges and adjacent brain parenchyma, M. tuberculosis typically produces small granulomas. Granulomatous foci can remain dormant for years, and the mechanism of reactivation is not well understood. Tuberculous meningitis develops when a caseating focus discharges its contents into the subarachnoid space. 51 Microglial cells are the principal targets of M. tuberculosis. Tumor necrosis factor " released from these cells plays a critical role in containing the infection, granuloma formation, alteration of blood-brain barrier permeability, and CSF leukocytosis. 52 Tuberculous meningitis is an aggressive form of extrapulmonary disease that is more common in patients coinfected with HIV. Although the exact incidence and prevalence of tuberculosis meningitis in many countries is not well defined, India, China, Indonesia, Nigeria, and South Africa have high rates of infection. Compared to people without HIV infection, those with HIV infection more commonly progress to have extrapulmonary infection, including meningitis. 53 Other predisposing factors for developing tuberculous meningitis include poverty, poor education, alcoholism, diabetes mellitus, immunosuppressive medications, and malignancy.
Clinical presentation. Tuberculous meningitis is typically preceded by nonspecific symptoms of malaise, anorexia, fatigue, weight loss, fever, myalgia, and headache. In immunocompetent patients, headache, vomiting, meningeal signs, focal deficits, vision loss, cranial nerve palsies, and raised intracranial pressure are characteristic clinical features. Vision loss may occur secondary to optic nerve involvement. Cerebral vessels may be affected by adjacent meningeal inflammation, producing vasospasm, constriction, and eventually thrombosis with cerebral infarction. Infarcts are most often located within the internal capsule, basal ganglia, and thalamus. 54 In a series of 101 adult patients, presenting neurologic features included headache (96.0%), fever (91.1%), nuchal rigidity (91.1%), vomiting (81.2%), meningismus (79.2%), and abnormal mental state (72.3%). 55 In patients with HIV infection with low CD4 cell counts, manifestations of tuberculous meningitis are subtle and less specific and typically present late in the course of the disease after a prolonged duration of severe illness. The most common clinical manifestations include fever and altered mental status. 54, 56 The hallmark pathologic feature of tuberculous meningitis is the presence of a thick exudate most prominent in the basilar meninges. This exudate can block the flow of CSF and result in hydrocephalus. The entrapment of intracranial vessels within exudates often produces cerebral infarction. Cranial nervesVmost often cranial nerves VII and VIIIVare also similarly affected, resulting in cranial nerve palsies. If the basal inflammatory process affects the brain parenchyma, it can result in encephalopathy. Cerebral tuberculomas are also common. Diagnosis. Although CSF acid-fast bacillus smear and culture are crucial for making a diagnosis of tuberculous meningitis, both have low sensitivity and presumptive treatment is often initiated when the clinical suspicion is high. Characteristic CSF abnormalities include a mononuclear cell pleocytosis, low glucose concentrations, and elevated protein concentrations. Unfortunately, acid-fast bacillus smear is positive in only 5% to 30% of patients. Conventional CSF culture for M. tuberculosis on Lowenstein-Jensen medium is positive in approximately 45% to 90% of cases but usually takes several weeks for a positive result. Sensitivity is higher for patients with HIV infection (69% sensitivity for smear and 87.9% for culture). CSF may be normal in 5% of HIV-positive patients with tuberculous meningitis. Detection of M. tuberculosis DNA in CSF by PCR assay is a useful ancillary diagnostic test, with a sensitivity that varies between 30% and 50% and specificity of 98%. The likelihood of detecting M. tuberculosis is increased if a combination of tests is performed on serial CSF samples. 57 Chest CT is sensitive for detecting pulmonary abnormalities in patients with tuberculous meningitis. Mediastinal and hilar lymphadenopathy, miliary pattern, and bronchopneumonic infiltrate are the most frequent abnormalities. Both CT and MRI of the brain are valuable for diagnosing tuberculous meningitis and evaluating for complications. Characteristic abnormalities include enhancement of the basilar meninges, exudates, hydrocephalus, and periventricular infarcts. MRI is considered more sensitive than CT, and gadoliniumenhanced imaging can detect meningeal enhancement early in the course of illness. Focal meningeal enhancement is more common than diffuse meningeal enhancement.
Treatment. Treatment should be initiated when tuberculous meningitis is initially suspected, as the organism grows slowly, speciation can take weeks, and earlier treatment is associated with better outcomes. First-line antituberculous medications include rifampicin, isoniazid, pyrazinamide, ethambutol (RIPE), and streptomycin. Most of the first-line antituberculous drugs (except ethambutol) achieve satisfactory levels in the CSF. Antituberculosis treatment for meningitis is divided into two phases: an intensive (initial) phase and a continuation phase. In the intensive phase, therapy includes a combination of four first-line medications: isoniazid, rifampicin, streptomycin, and pyrazinamide. The intensive phase continues for 2 months. In the continuation phase, the treatment regimen is reduced to two medications (isoniazid and rifampicin), and the continuation phase is usually extended to a total treatment period of 12 to 14 months. 58 Treatment of multi-and extremely drugresistant tuberculosis requires prolonged intensive and continuation phases and, depending on sensitivity, may require additional medications. A recent Cochrane review recommended that corticosteroids be used routinely for patients with tuberculous meningitis because they significantly reduced death and disabling residual neurologic deficits among survivors. 59 In addition, a randomized trial demonstrated significantly improved survival at 9 months in patients receiving dexamethasone, as well as decreased adverse effects of antituberculosis medications. 60 Neurosurgical intervention is often needed when hydrocephalus develops. Ventriculoperitoneal shunting is most frequently used, although other options include temporary external ventricular drainage and endoscopic third ventriculostomy. 54 Early neurosurgical procedures are also important for managing tuberculous brain abscesses. Stereotactic drainage or evacuation can reduce the size of space-occupying lesions, lower intracranial pressure, and improve eradication of the microorganism. 61 
Syphilis
Syphilis is caused by the thin, motile corkscrew bacterium Treponema pallidum. This organism cannot be routinely cultured in the laboratory and is difficult to visualize using traditional light microscopy. Transmission is primarily via sexual contact with an infected individual or by vertical transmission from mother to fetus. Without treatment, the disease will inevitably progress through a series of clinical stages. In general, syphilis can be classified as early or late infection. Early infection encompasses primary, secondary, and early latent syphilis. Late infection refers to tertiary syphilis.
After sexual exposure to the organism, an asymptomatic incubation period of approximately 3 weeks occurs, followed by development of a painless genital ulceration or chancre. The chancre and corresponding generalized lymphadenopathy are considered by most clinicians as primary syphilis. If left untreated, the chancre will resolve in 3 to 5 weeks and likely progress to secondary syphilis. Secondary syphilis is a syndrome of fever, lymphadenopathy, headache, malaise, myalgia, and a macular or pustular rash of the palms and soles. It is during this stage when involvement of other organ systems produces clinical symptoms, including mucosal lesions, renal failure, hepatitis, and neurologic symptoms. The signs and symptoms of secondary syphilis typically resolve in 4 to 10 weeks, and the patient is deemed latently infected. During this phase, patients are asymptomatic; however, they have serologic evidence of infection. Latent syphilis is typically subdivided into early and late disease. Early latent syphilis is typically diagnosed within 1 year of acquiring disease. Although usually asymptomatic, patients may experience recurrence of clinical symptoms during this time. About onethird of patients with untreated latent syphilis will progress to develop late or tertiary syphilis, which can affect any organ in the body, particularly the nervous system. 62 Clinical presentation of neurosyphilis. T. pallidum spreads hematogenously to the CNS early in the course of disease. Clinical signs and symptoms of CNS involvement are evident throughout the course of disease and not limited by stage. Neurosyphilis can be either early or late disease. The early stage typically manifests as asymptomatic or symptomatic meningitis and meningovascular disease. Late disease more often affects the brain parenchyma or spinal cord, leading to general paresis, psychiatric illness, memory deficits, tabes dorsales, and gummatous masses. 48 Although neurosyphilis has several manifestations, this article will limit the discussion to syphilitic meningitis. Syphilitic meningitis typically presents in the secondary stage of syphilis, within 2 years of acquiring infection. Although less common than other forms of neurosyphilis, meningitis occurs in up to 25% of patients. The most common presenting symptoms include headache, photophobia, nausea and vomiting, meningismus, and cranial nerve deficits. Although every cranial nerve can be affected, cranial nerves VII and VIII are most commonly affected.
Diagnosis. The diagnosis of neurosyphilis is typically made through a combination of history, physical examination, and results of serologic and CSF analyses. The first step in diagnosis is performing serologic testing for syphilis using VDRL and rapid plasma reagin assays. These assays detect IgG and IgM antibodies to a cardiolipin-lecithincholesterol antigen and are always positive in patients with neurosyphilis. They also provide quantitative titers that can be used to monitor response to treatment. h The first step in diagnosis of neurosyphilis is performing serologic testing for syphilis using Venereal Diseases Research Laboratory testing and rapid plasma reagin assays.
These assays are valuable for diagnosing early syphilis and early neurosyphilis. Treponemal assays, including the fluorescent treponemal antibody absorbed and T. pallidum particle agglutination tests, measure treponemal antibodies and are used for confirmatory testing. Treponemal assays should also be positive in patients with neurosyphilis.
Abnormal CSF is present in 70% of patients with early syphilis. In later disease, these abnormalities are less common, suggesting that some patients may spontaneously clear the organism from the CSF without treatment. Persistent CSF abnormalities can occur and are indicative of persistent infection. Although the significance of abnormal CSF findings for diagnosis, treatment, and prognosis in the asymptomatic patient is not certain, patients with abnormal CSF studies are at increased risk of progression to symptomatic neurosyphilis. 48 In active neurosyphilis, CSF typically has a lymphocytic pleocytosis and elevated protein concentration; however, in late disease, CSF studies may be normal. In syphilitic meningitis, CSF typically has a mononuclear predominant pleocytosis (greater than 10 cells/2L), elevated protein concentration (greater than 45 mg/dL), and normal or decreased glucose concentration. CSF immunologic tests, such as VDRL, are usually abnormal in syphilitic meningitis; however, because CSF VDRL assay has a sensitivity of less than 30% for detection of neurosyphilis, a negative result does not rule out neurosyphilis. CSF fluorescent treponemal antibody absorption testing is less specific but more sensitive than CSF VDRL and may be used to exclude the diagnosis. Dark-field microscopy for organism visualization in the CSF is insensitive. 63 More recently, PCR assays have been developed to detect T. pallidum in the CSF, but 50% of patients with syphilitic involvement of the CNS have a negative PCR. Rolfs and colleagues reported that 32 of 131 CSF specimens (24%) were positive for T. pallidum by PCR assay, but a positive PCR result did not correlate with CSF abnormalities or CSF VDRL reactivity. 64 Studies suggest that HIV-positive patients are more likely to have leukocytosis, elevated protein concentration, and low glucose concentration than HIV-negative patients. 65 Treatment. Penicillin is first-line therapy for neurosyphilis. The Centers for Disease Control and Prevention (CDC) recommends 18 million units to 24 million units of aqueous penicillin G per day administered as 3 million units to 4 million units IV every 4 hours or as continuous infusion for 10 to 14 days. 66 An alternative is procaine penicillin 2.4 million units IM daily with probenecid 500 mg orally 4 times daily for 10 to 14 days. In patients with penicillin allergy, most experts recommend substitution with ceftriaxone 2 g IV daily for 10 to 14 days. Marra and colleagues found that ceftriaxone therapy led to resolution of CSF abnormalities at a rate similar to patients receiving penicillin G treatment. 48 Prognosis of neurosyphilis is largely determined by the stage of the illness. Early stages of disease, such as syphilitic meningitis, respond much better to therapy than tertiary syndromes. Treatment of tabes dorsales and general paresis is not as effective. The CDC recommends reexamination of CSF every 6 months to monitor response to therapy until the CSF cell count is normal and the CSF VDRL is nonreactive. Retreatment should be considered if the cell count has not decreased at 6 months or if the CSF is not normal by 2 years.
Although most clinical presentations of syphilis have not been shown to vary significantly by HIV status, early meningeal neurosyphilis occurs more frequently among HIV-positive patients.
KEY POINT
h Prognosis of neurosyphilis is largely determined by the stage of the illness. Early stages of disease, such as syphilitic meningitis, respond much better to therapy than tertiary syndromes.
HIV-positive patients with early neurosyphilis are at increased risk of early neurologic complications and have slightly higher rates of treatment failure. The existing literature does not demonstrate a more effective treatment regimen in preventing neurosyphilis in HIV-positive patients when compared to existing recommendations for HIV-negative patients. HIV-positive patients with neurosyphilis should have repeat serologic follow-up at 3, 6, 9, 12, and 24 months after therapy. Although patients with HIV may continue to have abnormal CSF pleocytosis at 6 months after neurosyphilis treatment, retreatment should be considered in patients with CSF VDRL or serum VDRL titers that have failed to decline. Immune reconstitution using antiviral therapy is essential in the treatment of coexisting neurosyphilis. HIV-positive patients receiving antiviral therapy are 4 times more likely to demonstrate normalized CSF studies, 13 times more likely to have clinical improvement, and less likely to have serologic failure of treatment. 62 
AUTOIMMUNE DISEASE
Nervous system involvement has been described with virtually every autoimmune disease. Chronic meningitis may occur in a subset of these diseases. This section discusses the clinical presentation, diagnosis, and treatment of the most common autoimmune diseases associated with chronic meningitis, including sarcoidosis, systemic lupus erythematosus, Behçet disease, and CNS angiitis. Table 3 -4 provides a comprehensive list of autoimmune diseases reported to cause chronic meningitis with associated clinical symptoms and diagnostic recommendations. A 32-year-old man presented with 1 month of headache, progressive alteration in mental status, and disinhibited behavior. He noted several months of polydipsia, during which he consumed about 3 gallons of water per day. On examination, the patient was alert with fluent speech and normal comprehension. His disinhibited behavior was manifest as foul language and sexual referencing. The patient demonstrated concrete thinking to proverb interpretation. The cranial nerve examination was normal. His motor examination revealed spasticity of bilateral lower extremities with gegenhalten in the right upper extremity; he was diffusely hyperreflexic with bilateral upgoing toes.
A T2-weighted fluid-attenuated inversion recovery MRI sequence demonstrated diffuse hyperintensities involving the subcortical and gray matter of the bilateral frontal and parietal lobes, hypothalamus, midbrain, pons, medulla, and cerebellum (Figure 3-3A) . MRI of the cervical spinal cord displayed large areas of T2-weighted hyperintensity with patchy gadolinium enhancement (Figure 3-3B) . Lumbar puncture had normal opening pressure, 13 WBCs/2L (99% lymphocytes), glucose concentration 22 mg/dL, and protein concentration 428 mg/dL. Endocrinologic evaluation revealed Continued on page 1310 undetectable testosterone, low luteinizing hormone, low follicle-stimulating hormone, hyponatremia, and central hypothyroidism. All studies were consistent with hypothalamic dysfunction.
The patient declined clinically during the following month of hospitalization, with worsening spasticity, new incoordination, and progressive hyperreflexia with nonsustained clonus of the bilateral lower extremities. A repeat lumbar puncture displayed 41 WBCs/2L (64% lymphocytes, 9% neutrophils, 26% monocytes), glucose concentration 23 mg/dL, and protein concentration 357 mg/dL. CSF fungal and bacterial cultures were negative; CSF cryptococcal antigen, cytology, and PCR assays for human herpesvirus 6, cytomegalovirus, Epstein-Barr virus, varicella-zoster virus, and herpes simplex virus types 1 and 2 were negative. IgG index was normal at 0.69 (normal is less than 0.7) with no oligoclonal banding. Serology was negative for Borrelia burgdorferi IgM and IgG, HIV antibody, Bartonella species IgG and IgM, and VDRL. Autoimmune workup was negative for neuromyelitis optica antibody, thyroglobulin antibody, thyroid peroxidase antibody, antineutrophil cytoplasmic antibody, antinuclear antibody, angiotensin-converting enzyme (ACE) (serum and CSF), erythrocyte sedimentation rate, C-reactive protein, and Sjö gren syndrome antigens A and B. In light of the patient's declining neurologic examination and the negative infectious and neoplastic workup, empiric IV methylprednisolone sodium succinate was started. Definitive diagnosis was ultimately made via conjunctival biopsy. Pathology results indicated noncaseating granulomatous conjunctivitis consistent with sarcoidosis ( Figure 3-4) . The patient was ultimately diagnosed with systemic sarcoidosis with neurologic involvement. He was maintained on prednisone and improved both clinically and radiologically.
Comment. This case of neurosarcoidosis highlights the unique hypothalamic involvement of disease presenting with multiple endocrine abnormalities. Despite advanced methods of CSF testing and imaging, ultimate diagnosis was made using systemic biopsy. Continued from page 1309 almost any part of the nervous system. The most common clinical presentations include cranial neuropathies, seizures, meningitis, mass lesions, hypothalamic or pituitary involvement, spinal cord lesions, psychiatric manifestations, movement disorders, peripheral neuropathy, and myopathies. Cranial neuropathies occur in 50% to 75% of patients and are most often the result of elevated intracranial pressure, granulomas, or basilar meningitis. The most common cranial neuropathy is unilateral or bilateral facial palsy. Acute and chronic meningitis occurs in up to 26% of patients with neurosarcoidosis. Case 3-3 demonstrates a classic case of neurosarcoidosis.
Diagnosis. Diagnosis of neurosarcoidosis is difficult and often requires a combination of medical history with neuroimaging, serologic and CSF data, and tissue biopsy. The diagnosis of systemic sarcoidosis is typically made through biopsy of lymph nodes, lung, liver, skin, or conjunctiva with histologic demonstration of noncaseating granulomas consisting of epithelioid cells and macrophages. Brain biopsy may be useful when meningeal or cerebral abnormalities are easily accessible but is not routine. Serum ACE levels are elevated in 50% of patients with neurosarcoidosis. 67 CSF analysis typically reveals a lymphocytic pleocytosis (10 cells/2L to 200 cells/2L) with significantly elevated protein concentration (2 g/L or greater) and low glucose concentration. Opening pressure is often elevated. CSF tests for oligoclonal bands may be positive, most often in the setting of an elevated protein concentration. Additional useful CSF markers include CSF lysosome, "2-microglobulin, and T-cell lymphocyte ratios. CSF ACE levels are nonspecific but can be elevated with neurosarcoidosis.
MRI with gadolinium reveals leptomeningeal enhancement in up to 40% of patients with neurosarcoidosis, with the basilar meninges most often involved.
Dural enhancement is present in up to 30% of cases. Intraparenchymal mass lesions or granulomas may be solitary or multiple and typically enhance with gadolinium. Pituitary and hypothalamic masses, enhancement, or thickening are present in 18% of patients with neurosarcoidosis. Although the facial nerve is the most common clinical manifestation of cranial neuropathy, on MRI, the optic nerve is most frequently abnormal, displaying enhancement and thickening. Other nonspecific findings include hydrocephalus, cavernous sinus involvement, lacrimal gland enlargement, osseous lesions, intramedullary spinal lesions, and spinal nerve root enhancement. 68 Treatment. Corticosteroids are the mainstay of treatment for sarcoidosis, with recommended doses of 40 mg/d to 60 mg/d followed by a slow taper. Patients with severe symptoms may be treated with high-dose methylprednisolone (1 g IV for 3 to 5 days) followed by oral prednisone. Steroid-sparing immunosuppressive medications, including mycophenolate, azathioprine, methotrexate, cyclophosphamide, infliximab, and hydroxychloroquine, have been used with varying degrees of success; these medications are often used for long-term suppression.
Systemic Lupus Erythematosus
Adult and pediatric systemic lupus erythematosus (SLE) commonly may affect any part of the nervous system and has been termed neuropsychiatric lupus. The American College of Rheumatology established case definitions for 19 central and peripheral nervous system syndromes in neuropsychiatric SLE, including cognitive and psychiatric disorders, demyelination, seizures, transverse myelitis, headache, movement disorders, vasculitis, aseptic meningitis, and peripheral neuropathy. The pathogenesis of CNS manifestations is multifactorial and may involve autoantibodies against the nervous system, microangiopathy, intrathecal production of proinflammatory cytokines, and premature atherosclerosis. Antiphospholipid antibodies are the most frequently observed autoantibody in SLE and have been associated with stroke and cognitive decline. Disruption of the integrity of the bloodbrain barrier is essential for SLE-related neuropathology to develop. Abnormal endothelial cell interactions may be involved in allowing proteins and lymphocytes to gain access into the CNS. 69 Clinical presentation. Meningitis associated with SLE is typically aseptic, 70 but because many patients are treated with chronic immunosuppressive therapy, they are at risk for developing infectious meningitis. Infectious meningitis should be considered in patients with SLE who have been treated with immunosuppressive therapy and present with fever, altered mental status, meningeal signs, and nausea or vomiting. Compared to SLE-associated aseptic meningitis, patients with infectious meningitis are typically older, develop mental status changes, and have plasma leukocytosis with neutrophilia, as well as a marked CSF pleocytosis and hypoglycemia. Nonsteroidal anti-inflammatory medications have been implicated as a causative factor in aseptic meningitis associated with SLE. 71 Diagnosis and treatment. No single diagnostic test that is sensitive and specific for SLE-related neurologic disease is available. Assessment should include neurologic and rheumatologic evaluations, serologic testing of immune parameters, and neuroimaging. CSF examination is crucial for excluding the diagnosis of infectious meningitis prior to initiating immunosuppressive therapy. A recent study evaluated the presence of autoantibodies in the serum and CSF in patients with lupus and neurologic symptoms. Antibodies were checked again at 6 months when clinical manifestations of disease had resolved. The following serum autoantibodies were detected: antinuclear antibody (82%), antiYdouble-stranded DNA (79%), antiribosomal (61%), anticardiolipin IgG (15%), antiY" 2 glycoprotein IgG (65%), and anti-NMDA receptor (35%). These antibodies did not change with resolution of symptoms. The following CSF autoantibodies were detected: antinuclear antibody (57%), antiYdouble-stranded DNA (77%), antiribosomal (46%), anticardiolipin IgG (11%), antiY" 2 glycoprotein I (0%), and antiYNMDA receptor antibody (41%). Similar to serum values, CSF autoantibodies did not resolve with improvement of symptoms. The role of serum and CSF autoantibody detection in patients with lupus is not clear. 72 Aseptic meningitis associated with SLE is typically self-limited.
Behçet Disease
Behçet disease, a multisystem disease characterized by recurrent oral aphthous ulcers, genital ulcers, and uveitis, typically presents between 20 and 40 years of age. Men are affected more commonly than women. This disease can affect almost any organ, including the eye; skin; major vessels; and cardiac, pulmonary, musculoskeletal, and gastrointestinal systems. Neurologic involvement occurs in 5% to 10% of patients with Behçet disease and can be parenchymal or nonparenchymal. Parenchymal disease, or meningoencephalitis, occurs in 70% of patients with neuroYBehçet disease and typically involves a massive inflammatory infiltration of polymorphonuclear lymphocytes, eosinophils, lymphocytes, and macrophages into the brainstem, diencephalon, and small vessels; fibrinoid necrosis is typically absent. Nonparenchymal disease typically manifests as cerebral venous thrombosis. Other rare presentations include spinal cord lesions, arteritis, optic neuritis, aseptic meningitis, and peripheral neuropathies.
NeuroYBehçet disease typically presents subacutely with a constellation of fever, malaise, orogenital ulcerations, skin lesions, or uveitis. Over weeks, patients develop a progressive headache, followed by a variety of potential accompanying symptoms, including altered mental status, dysarthria, ophthalmoplegia, ataxia, and hemiparesis. The course of illness may be notable for recurrent attacks, secondary progressive disease, or a primary progressive decline. Diagnosis involves fulfilling the diagnostic criteria for systemic Behçet disease plus neurologic symptoms not explained by other conditions or infections. Typical radiographic and CSF analysis are also useful. Early in the disease course, CSF has a polymorphonuclear pleocytosis followed by a lymphocytic predominance. The cell count ranges from 0 cells/2L to 400 cells/2L with elevated protein concentration (greater than 1 g/dL) and normal glucose concentration. MRI of the brain typically demonstrates a large asymmetric lesion involving the midbrain, pons, thalamus, or basal ganglia. These lesions are generally hyperintense on T2-weighted images and hypointense on T1-weighted images. Gadolinium enhancement and small hemorrhages may be present. Chronically, MRI often demonstrates widespread subcortical white matter lesions with brainstem atrophy. 73 No standard treatment is available for neuroYBehçet disease. Most commonly, glucocorticoids are administered to treat acute exacerbations, with an initial pulse of high-dose IV steroids followed by gradual taper. Many medications used to treat systemic Behçet disease, including azathioprine, colchicine, cyclosporine, cyclophosphamide, methotrexate, interferon alpha, and antiYtumor necrosis factor agents, have been used as adjunctive treatment of neuroYBehçet disease. Some experts suggest starting azathioprine with steroids at the first attack. Low-dose steroids should be continued for 5 weeks until azathioprine is active. In patients who have progression of symptoms or cannot tolerate azathioprine, mycophenolate mofetil is an alternative treatment. 74 Primary Angiitis of the CNS Primary angiitis of the CNS (PACNS) is characterized by inflammation and destruction of cerebral vessels without systemic involvement. PACNS consists of several subtypes grouped into typical and atypical forms. Typical PACNS is the granulomatous type. Atypical forms include lymphocytic, angiographically defined, mass lesions, and amyloid "Yrelated cerebral angiitis.
Granulomatous angiitis, the classic form of PACNS, is characterized by chronic meningitis with an insidious onset of symptoms. Patients may present with a history of years of headache, encephalopathy, seizures, cognitive and behavioral changes, ataxia, recurrent TIAs, or focal neurologic deficits. Symptoms of chronic meningitis can precede diagnosis by several years. Granulomatous angiitis of the CNS is diagnosed by pathologic findings of small and medium leptomeningeal and cortical artery infiltration of giant cells, which can be segmental with necrotizing or lymphocytic involvement. 75 Diagnostic criteria proposed in 1988 includes the presence of acquired and unexplained neurologic or psychiatric deficits, presence of angiographic or histopathologic evidence of angiitis in the CNS, and no evidence of systemic or other disorders that may mimic the disease. Primary angiitis of the CNS peaks in the fifth and sixth decades of life and is more common in men. The combination of serologic studies, CSF analysis, angiography, MRI, and brain biopsy are essential for diagnosing PACNS. Biopsy is the gold standard for diagnosis but has low sensitivity. More importantly, biopsy is useful in identifying lesions that may mimic PACNS, such as infection or malignancy, which are found in up to 40% of patients. Serum erythrocyte sedimentation rate and C-reactive protein are typically normal in PACNS and elevated in conditions that mimic PACNS. CSF analysis is abnormal in over 90% of patients and usually demonstrates a modest lymphocytic pleocytosis (less than 20 cells/2L), elevated protein concentration (median less than 120 mg/dL), and normal glucose concentration. CSF examination is crucial for excluding infectious and neoplastic mimics of PACNS. Cranial MRI may reveal infarction in up to half of patients, and nonspecific subcortical white matter, deep white matter, and cortical T2-weighted hyperintensities are often present. Mass lesions are present in 5% of patients with PACNS and are potential sites for biopsy to confirm the diagnosis of PACNS and exclude other potential etiologies. Gadolinium enhancement of the leptomeninges occurs in 8% of patients. Cerebral angiography is commonly used to aid in the diagnosis of PACNS and classically demonstrates alternating areas of dilation and stenosis that can be smooth or irregular. These findings are nonspecific for PACNS and can be seen with other disorders, including infection, radiation, atherosclerosis, and vasospasm. Sensitivity of angiography varies from 40% to 90%. Although the diagnosis of PACNS can be difficult to confirm, patients with normal CSF, angiography, and MRI are extremely unlikely to have PACNS. 76 Treatment of PACNS includes immunosuppression with a combination of glucocorticosteroids and cyclophosphamide. High-dose oral prednisone (1 mg/kg/d) or IV pulse methylprednisolone for 3 days, followed by oral prednisone, is recommended. Cyclophosphamide, azathioprine, or mycophenolate mofetil are most commonly used for longterm immunosuppression. Disease activity can be monitored with serial neurologic examinations and MRI scans. 76 
NEOPLASTIC
Neoplastic involvement of the CNS should be considered in the differential diagnosis for patients presenting with signs and symptoms of chronic meningitis. Leptomeningeal carcinomatosis or carcinomatous meningitis is defined as malignant seeding or infiltration of the leptomeninges. Leptomeningeal carcinomatosis is most commonly associated with hematologic malignancies, but solid tumors and primary brain tumors infiltrate the meninges in up to 5% of patients. Patients classically present with signs and symptoms of multifocal involvement of the neuraxis due to involvement of the cerebral hemispheres, brainstem, cranial nerves, spinal cord, or nerve roots. The most common presenting symptoms include headache, encephalopathy, nuchal rigidity, diplopia, weakness, and radicular pain. Cranial neuropathies may include trigeminal neuropathy, facial weakness, and hearing loss. 77 Diagnosis of leptomeningeal carcinomatosis is made by clinical examination, CSF analysis, and gadolinium-enhanced MRI. Lumbar puncture typically reveals elevated opening pressure, leukocytosis, and elevated protein and low glucose concentrations. CSF cytology should be sent for all patients with CSF pleocytosis of unknown etiology to evaluate for neoplastic cells. The sensitivity of a single large volume CSF sample is 38% to 66%; if three large volume CSF samples are performed, the sensitivity increases to 90%. 78 Gadolinium-enhanced MRI is the imaging modality of choice and typically displays contrast enhancement of the meninges, cortical convexities, basilar cistern, and cauda equina. 79 Meningeal biopsy of contrast-enhancing lesions remains the gold standard for definitive diagnosis of leptomeningeal carcinomatosis. Early diagnosis and treatment of leptomeningeal carcinomatosis is important for symptomatic relief and prognostic implications, but long-term prognosis is poor. Without treatment, overall survival is typically 4 to 6 weeks. Treatment for leptomeningeal carcinomatosis includes focal radiotherapy for bulky disease, local chemotherapy, and systemic chemotherapy. 80 
